A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML)

Clinical trial NCT05190471 · RECRUITING

Trial details

NCT number: NCT05190471
Sponsor: Bio-Path Holdings, Inc.
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Acute Myeloid Leukemia, in Relapse Acute Myeloid Leukemia Refractory

Start date: 2022-08-16
Primary completion: 2027-03-01
Enrollment: 48

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.